Transcatheter Aortic Valve Devices Market Snapshot 2024-2028
Overview
Valued at ~$5.89 billion in 2023, the transcatheter aortic valve devices market is projected to
reach ~$8.38 billion by 2028, increasing at a CAGR of 7.3% over the 2023-2028
forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
Transcatheter aortic valve devices are used to replace or repair the natural tissue valve of the heart,
particularly the aortic valve, which may be damaged due to disease or aging. Transcatheter aortic valve
replacement (TAVR), or transcatheter aortic valve implantation (TAVI), involves delivering a fully collapsible
replacement valve through a catheter. Once inside the heart, the valve is deployed into its natural position by
inflating a balloon, allowing it to function within the patient’s diseased valve.
Products included within the scope of this analysis include:
Transcatheter aortic valve repair and replacement devices
This Market Snapshot is intended to provide a high-level overview of the global market for transcatheter aortic
valve devices, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Transcatheter Aortic Valve Devices Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $5.89 billion |
| CAGR | 7.3% |
| Projected Market Size in 2028 | $8.38 billion |
Transcatheter Aortic Valve Devices Market Insights
The transcatheter aortic valve market is the largest segment within the overall heart valve market, which
includes
mechanical
heart valves, tissue
heart valves, and transcatheter mitral,
tricuspid,
and pulmonary
valves. Over the past few years, this segment has seen rapid growth driven by the increasing adoption of less
invasive transcatheter aortic valve repair and replacement procedures. These procedures have enabled treatment
for a broader range of patients, particularly those who are too frail or not candidates for traditional
open-heart surgery. However, the market is showing signs of maturing as the technology becomes more widely
adopted.
Total heart valve repair and replacement procedures are expected to grow at a 5.5% compound annual rate from
2023 to 2028, reflecting the increasing prevalence of heart valve disease globally. As the population ages, with
more than 5 million Americans diagnosed annually and a significant portion suffering from severe aortic
stenosis, the demand for transcatheter aortic valve procedures is expected to rise. This growth is further
fueled by the expanding use of less invasive technologies, which allow more patients to be treated effectively
and safely.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the transcatheter aortic
valve devices market. This includes estimated market revenue and market share for key players, such as Edwards
Lifesciences and Medtronic.
Select Market Events
| Company | Date | Type | Event |
|
Edwards Lifesciences
|
5/2024 | Product Launch | Edwards announced the launch of its SAPIEN 3 Ultra RESILIA Valve in Europe. |
|
Medtronic
|
3/2024 | Regulatory Approval | Medtronic received U.S. FDA approval for its Evolut TAVR system. |
Key Companies Covered
Abbott
Anteris Technologies
Edwards Lifesciences
JenaValve
Medtronic
NVT
Vascular Interventions
